Jay D. Amsterdam

faculty photo
Director, Bipolar Disorders and Lithium Clinic

Contact information
Depression Research Unit
3535 Market Street, 3rd Floor
Philadelphia, PA 19104-3309
Office: (215) 662-3462
Fax: (215) 662-6443
Education:
B.A.
Syracuse University, Syracuse, New York, 1970.
M.D.
Jefferson Medical College, Philadelphia, Pennsylvania, 1974.
Permanent link
 

Description of Research Expertise

1977-present
1) Psychopharmacology of Affective Disorders
2) Antidepressant Drug Development
3) Investigational Clinical Trials
4) Bipolar Affective Disorders
5) Treatment-resistant Affective Disorders
6) Brain Imaging Studies
7) Psychoneuroendocrinology of Affective disorders
8) Psychoimmunovirology
9) Clinical Pharmacokinetics
10)Complementary & Alternative Medicine

Description of Itmat Expertise

Dr. Amsterdam is investigating mood disorders through the use of psychopharmacology, new antidepressant drug development, psychoneuroendocrinology, psychoimmunovirology, brain imagining and studies of bipolar disorder and resistant depression.

Selected Publications

Amsterdam, J.D., Newberg, A: Dopamine Transporter Density in Bipolar Type II and Unipolar Major Depressive Episode. Neuropsychobiology 55: 167-170, 2007.

Michelson D, Adler L, Amsterdam JD, Dunner D, Nierenberg A, Reimherr F, Schatzberg Am Kelsey D, Williams D: Addition of atomoxetine for depression incompletely responsive to sertraline: A randomized, double blind, placebo controlled study. Journal of Clinical Psychiatry 68: 582-587, 2007.

Newberg AB, Amsterdam JD, Shults J: Dopamine transporter density may be associated with the depressed affect in healthy subjects. Nuclear Medicine Communications 28(1): 3-6, 2007.

Amsterdam JD: Monoamine oxidase inhibitor therapy in severe and resistant depression. Psychiatric Annals 36(9): 606-617, 2006.

Amsterdam JD, Bodkin JA: Selegiline transdermal system and the prevention of relapse of major depressive disorder: a 52-week, double-blind placebo substitution parallel group clinical trial. Journal of Clinical Psychopharmacology 26: 579-586, 2006.

DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O'Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R, : Cognitive therapy vs. medications in treatment of moderate to severe depression. Archives of General Psychiatry 62: 409-416, 2005.

Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R : Prevention of relapse following cognitive therapy versus medications in moderate to severe depression. Archives of General Psychiatry 62: 417-422, 2005.

Amsterdam JD, Rutherford N, Shults J: Antidepressant monotherapy of major depressive episode in bipolar II disorder: A therapeutic change. Psychiatric Annals 35(12): 981-992, 2005.

Amsterdam JD, Shults J: MAOI safety and efficacy in advanced treatment-resistant depression - a retrospective analysis. Journal of Affective Disorders 89: 183-188, 2005.

Amsterdam JD, Shults J: Fluoxetine monotherapy for bipolar type II and bipolar NOS major depression - A double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology 20: 357-364, 2005.

back to top
Last updated: 03/26/2010
The Trustees of the University of Pennsylvania